{"id":4823,"date":"2010-12-16T16:00:51","date_gmt":"2010-12-16T21:00:51","guid":{"rendered":"http:\/\/insidesurgery.com\/?p=4823"},"modified":"2011-04-07T19:24:23","modified_gmt":"2011-04-07T23:24:23","slug":"fda-recommends-suspending-avastin-breast-cancer","status":"publish","type":"post","link":"https:\/\/insidesurgery.com\/2010\/12\/fda-recommends-suspending-avastin-breast-cancer\/","title":{"rendered":"FDA Recommends Suspending Use of Avastin for Breast Cancer"},"content":{"rendered":"
The United States Food and Drug Administration is recommending that use of Avastin (bevacizumab) be suspended in the treatment of breast cancer because of too severe side effects with too little efficacy. FDA officer Dr. Janet Woodcock comments.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"_genesis_hide_title":false,"_genesis_hide_breadcrumbs":false,"_genesis_hide_singular_image":false,"_genesis_hide_footer_widgets":false,"_genesis_custom_body_class":"","_genesis_custom_post_class":"","_genesis_layout":"","footnotes":""},"categories":[31],"tags":[3623,1527,1855,3624],"yoast_head":"\n
\nThe United States Food and Drug Administration is recommending that use of Avastin (bevacizumab) be suspended in the treatment of breast cancer because of too severe side effects with too little efficacy.<\/a> FDA officer Dr. Janet Woodcock comments.
\n<\/p>\n","protected":false},"excerpt":{"rendered":"